US Patent 10,434,059: Claim Scope, Patent Expiration, Litigation Risk, and Catechin Formulation Landscape
US Patent 10,434,059 protects topical compositions combining isopropyl myristate with a defined green-tea catechin mixture, plus narrowly specified ointment bases and methods for treating HPV-associated warts and benign tumors. The commercial core is a 15% catechin formulation containing 35% isopropyl myristate and a petrolatum-wax vehicle. The patent is composition-led, with additional method-of-use claims directed to topical, genital, and vaginal treatment.
The strongest infringement risk arises where a competing product contains both:
- Isopropyl myristate at or above the claimed concentration; and
- A catechin mixture whose component proportions fall within the claimed ranges.
A product containing sinecatechins without isopropyl myristate would generally avoid the central combination claims, subject to other patent rights. A product using isopropyl myristate but a materially different catechin profile may also avoid literal infringement, although the doctrine of equivalents and other family patents would require separate analysis.
What does US Patent 10,434,059 protect?
The patent protects four principal subject-matter groups:
| Claim group |
Claims |
Protected subject matter |
| Broad composition |
1-18 |
Isopropyl myristate plus a specified catechin mixture |
| Defined commercial formulation |
19 |
35% isopropyl myristate, 15% catechin mixture, and specified excipients |
| Treatment method |
20-25 |
Topical treatment of HPV-induced skin disease and benign tumors |
| Alternative fixed formulation |
26 |
35% isopropyl myristate, 15% catechin mixture, and a specified white petrolatum/wax vehicle |
The independent claims are claims 1, 19, 20 and 26. Claims 2-18 and 21-25 depend from earlier claims and narrow the scope.
What are the key chemical limitations?
Claim 1 requires a mixture containing six catechol or catechin components in specified weight-percentage ranges:
| Component |
Claim 1 range |
| (-)-Epicatechol |
4%-15% |
| (-)-Epicatechol gallate |
2%-20% |
| (-)-Epigallocatechol |
3%-15% |
| (-)-Epigallocatechol gallate |
40%-75% |
| (-)-Gallocatechol |
0.1%-1% |
| (-)-Gallocatechol gallate |
1%-10% |
The claim also requires isopropyl myristate at 5%-50% by weight.
The terminology in the claims appears to use “catechol” where the relevant green-tea compounds are commonly described as catechins. The commercial and regulatory literature for sinecatechins generally uses names such as epicatechin, epigallocatechin, epigallocatechin gallate, gallocatechin and gallocatechin gallate. Claim construction would likely require the specification and prosecution history to determine whether the nomenclature is treated as a drafting error, a defined term, or a meaningful chemical distinction.
How narrow are the dependent composition claims?
The dependent claims create several overlapping concentration positions.
Catechin-mixture concentration
Claims 2-4 narrow the total catechin mixture:
| Claim |
Catechin mixture limitation |
| 2 |
1%-30% |
| 3 |
2%-20% |
| 4 |
15%-18% |
Claim 4 is particularly important because it captures a conventional 15% topical catechin product.
Isopropyl myristate concentration
Claims 2 and 5-6, as well as claims 11-13, impose progressively narrower isopropyl myristate ranges:
| Claim |
Isopropyl myristate limitation |
| 1 |
5%-50% |
| 2, 11 |
At least 10%, up to 50% |
| 5, 12 |
At least 25%, up to 50% |
| 6, 13 |
At least 35%, up to 50% |
A formulation containing 35% isopropyl myristate and 15% catechins falls within the principal concentration limitations of claims 1-6 and 11-13, assuming the catechin profile also falls within claim 1.
Narrow catechin subranges
Claims 7-9 narrow individual components:
- Epicatechin gallate: 5%-7%
- Gallocatechin: 0.1%-0.6%
- Gallocatechin gallate: 1%-5%
Claim 10 identifies a representative catechin profile, including:
- 10.8% epicatechin
- 6.5% epicatechin gallate
- 9.2% epigallocatechin
- 54.8% epigallocatechin gallate
- 4.0% gallocatechin gallate
Those values are within the broader ranges of claim 1. Claim 10 does not state a complete six-component composition because gallocatechin is not assigned a fixed percentage in the quoted claim language. The phrase “and/or” also creates potential claim-construction issues regarding whether all listed components are required.
What formulation does claim 19 protect?
Claim 19 is directed to a fixed 100%-by-weight formulation:
| Ingredient |
Weight percentage |
| Isopropyl myristate |
35.0% |
| Catechin mixture |
15.0% |
| Petroleum jelly |
24.5% |
| Wax |
20.0% |
| Propylene glycol monostearate or monopalmitostearate |
5.0% |
| Oleyl alcohol |
0.5% |
| Total |
100.0% |
The claim is commercially significant because it identifies a complete dosage form rather than merely a broad active/excipient combination.
A competing product that uses the same 35% isopropyl myristate and 15% catechin concentration but substitutes a materially different vehicle may avoid literal infringement of claim 19 while remaining exposed under claims 1-18, depending on the catechin profile and the presence of other claimed additives.
What is the scope of the treatment-method claims?
Claims 20-25 cover treatment of papillomavirus-induced skin disease or benign tumors using the claim 19 composition.
Covered disease categories
Claim 21 lists numerous HPV types, including HPV 1-6, 8-19, 20-29, 31-32, 34, 36-38, 46-50, 56 and 58.
Claim 22 identifies warts, genital warts and benign tumors of the skin or mucosa.
Claim 23 expands the disease list to include:
- Plantar warts
- Common warts
- Flat juvenile warts
- Epidermodysplasia verruciformis
- Condylomata acuminata
- Condylomata plana
- Bowenoid papulosis
- Laryngeal and oral-mucosal papillomas
- Focal epithelial hyperplasia
Claims 24 and 25 require topical administration, including genital or vaginal application.
The method claims are narrower than a general claim to treating HPV disease. They require use of the specific claim 19 formulation and the specified disease-treatment relationship. Regulatory approval for a different indication would not automatically determine patent infringement. Infringement generally turns on the product label, instructions, marketing, actual use and other evidence relevant to induced or contributory infringement.
What are the main design-around options?
The claim structure creates several practical design-around pathways.
| Design-around strategy |
Likely effect |
| Remove isopropyl myristate |
Avoids the central combination requirement |
| Use another penetration enhancer |
May avoid literal infringement if no equivalent argument succeeds |
| Change epigallocatechin gallate outside 40%-75% |
May avoid claim 1 if the entire composition falls outside the ranges |
| Alter multiple catechin ratios |
Reduces literal infringement risk |
| Use a catechin concentration outside 1%-30% |
Avoids dependent claims 2-4, but not necessarily claim 1 |
| Replace the wax/petrolatum vehicle |
May avoid claims 19 and 26 |
| Use an oral or non-topical route |
May avoid claims 24-25, but not composition claims |
| Use a different indication |
May avoid method claims but not composition claims |
| Use a different HPV indication or disease |
May reduce method-claim exposure |
The most reliable composition design-around is to remove isopropyl myristate or move the catechin profile outside the combined claim ranges. Changing only one excipient is less effective because claims 1-18 do not require the complete vehicle recited in claims 19 and 26.
How should the fixed percentages be analyzed?
Claim 19 totals 100%, which supports a complete formulation interpretation. Claim 26, as quoted, presents:
- 35% isopropyl myristate
- 15% catechin mixture
- 35% white petrolatum
- 25% white wax
- 5% propylene glycol monopalmitostearate
- 0.5% oleyl alcohol
Those ingredients total 115.5%. This is an internal drafting issue. The wording “comprising” does not cure a mathematical impossibility where the listed ingredients are each stated as fixed weight percentages of the total composition. The prosecution history, issued patent text, certificate of correction and any post-grant proceeding would be important to determine whether claim 26 contains a correctable clerical error or is vulnerable to indefiniteness, lack of written description or lack of enablement arguments.
The discrepancy does not necessarily affect claims 1-25. Claim 19 is independently structured and totals 100%.
What is the relationship to sinecatechins and Veregen?
The claimed catechin mixture is closely related to the active botanical profile used in topical sinecatechin products, including Veregen. FDA labeling for Veregen identifies sinecatechins as a botanical drug substance derived from green tea extract and markets the product for external genital and perianal warts caused by HPV [2].
The patent does not broadly claim all sinecatechins products. Its distinctive limitation is the combination of the catechin mixture with high levels of isopropyl myristate. That limitation separates the patent from a conventional 15% sinecatechins ointment that uses a petrolatum-based vehicle without the claimed penetration-enhancer concentration.
Comparison with a conventional sinecatechins ointment
| Issue |
US 10,434,059 |
Conventional sinecatechins product |
| Active |
Defined catechin mixture |
Green-tea catechin extract |
| Catechin level |
Often 15% in the narrower claims |
Commonly 15% |
| Isopropyl myristate |
Required by composition claims |
Not necessarily present |
| Vehicle |
Petrolatum, wax and lipophilic excipients in some claims |
Petrolatum-based ointment |
| HPV indication |
Broad listed HPV diseases in method claims |
Regulatory labeling may be narrower |
| Patent risk |
High if claimed IPM and catechin profile are present |
Depends on formulation and other patents |
What is the Orange Book status?
The supplied claim text does not establish that US Patent 10,434,059 is listed in the FDA Orange Book. Orange Book listing is product-specific and depends on the approved drug application, the NDA holder, the drug product, and the patent-listing submission. A patent may cover a formulation or method without appearing in the Orange Book for a particular product.
For a product such as topical sinecatechins, the relevant analysis requires separating:
- The patent’s existence and enforceability;
- Its listing against a specific NDA;
- Whether the listed claims cover the approved product or its approved use; and
- Whether a generic applicant would face a Paragraph IV certification.
The patent number alone does not establish Orange Book listing, a Paragraph IV challenge or a statutory stay.
Are there biosimilar risks?
No conventional biosimilar pathway is implicated. Sinecatechins are a botanical small-molecule or complex botanical drug substance, not a therapeutic protein or other biologic ordinarily regulated through the biosimilar pathway under section 351(k) of the Public Health Service Act.
The relevant competitive threats are more likely to involve:
- Generic or abbreviated applications, if FDA determines the product and pathway are eligible;
- 505(b)(2) applications for a reformulated or repurposed topical product;
- Compounded topical products;
- OTC or physician-dispensed wart treatments;
- New botanical formulations using different catechin ratios.
A competing botanical product could face pharmaceutical equivalence, bioequivalence, CMC and active-ingredient characterization issues independent of the patent estate.
What patent expiration date applies?
The patent issued on October 8, 2019, as US Patent 10,434,059. The expiration date cannot be calculated from the claim text or issue date alone. US patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers and priority claims [1].
The operative date must therefore be taken from the patent front page, continuity data and USPTO Patent Center record. Patent-term adjustment can extend the nominal term, while a terminal disclaimer can shorten it. FDA regulatory exclusivity is separate from patent term and may expire earlier or later.
Which litigation and Paragraph IV challenges affect the patent?
The supplied information does not establish a filed infringement action, Paragraph IV certification, settlement agreement or post-grant challenge involving US Patent 10,434,059.
A complete litigation assessment would distinguish among:
- District-court infringement actions;
- Inter partes review petitions;
- Post-grant review proceedings;
- Ex parte reexaminations;
- Patent-term disputes;
- ANDA Paragraph IV notices;
- 505(b)(2) patent certifications; and
- License or settlement agreements.
The most material litigation issues apparent from the claims are claim construction of the catechin nomenclature, interpretation of “comprising,” treatment of percentage ranges, the “and/or” language in claim 10 and the mathematical inconsistency in claim 26.
How strong is the patent estate?
Strengths
- Claims 1-18 provide multiple overlapping concentration combinations.
- Claims 5-6 and 12-13 directly target formulations with at least 25% or 35% isopropyl myristate.
- Claim 19 identifies a commercially realistic 100%-by-weight formulation.
- Method claims cover genital, vaginal and other topical HPV-related uses.
- The composition claims do not depend on the treatment indication.
Weaknesses
- The claim terminology appears chemically imprecise.
- Claim 10 contains “and/or” language that may create scope ambiguity.
- Claim 26 totals more than 100% by weight as quoted.
- A competitor can potentially design around the patent by removing isopropyl myristate or shifting the catechin profile.
- Method claims may be limited by the exact formulation and labeled use.
- The patent’s commercial value depends on whether the claimed composition is used in an approved or marketed product.
Key Takeaways
- US Patent 10,434,059 is principally a formulation patent covering catechins plus isopropyl myristate.
- The commercial center of gravity is a 15% catechin mixture with 35% isopropyl myristate.
- Claims 19 and 26 target specific ointment vehicles, while claims 1-18 provide broader composition coverage.
- The patent does not claim all sinecatechins products because isopropyl myristate is a central limitation.
- The method claims cover topical treatment of a broad set of HPV-associated diseases, including genital warts.
- Claim 19 totals 100%; claim 26, as quoted, totals 115.5% and presents a material validity and construction issue.
- No biosimilar pathway is expected to be central to competition.
- Patent expiration, Orange Book listing, Paragraph IV activity and litigation status cannot be established from the supplied claims alone.
FAQs
Does US Patent 10,434,059 cover Veregen?
Not necessarily. It may cover a Veregen-like catechin formulation only if the product also satisfies the claimed isopropyl myristate and catechin-composition limitations. A conventional sinecatechins ointment without the claimed isopropyl myristate concentration would generally fall outside the core composition claims.
Can a competitor use 15% sinecatechins without infringing?
Potentially. A 15% sinecatechins product that lacks isopropyl myristate, uses a different catechin profile or falls outside the claimed ranges may avoid literal infringement. The full formulation and product labeling must be compared against each asserted claim.
Is isopropyl myristate required in every independent claim?
Yes, in the quoted independent composition claims 1, 19 and 26. The method claims require administration of the composition of claim 19 and therefore indirectly incorporate its isopropyl myristate limitation.
Does changing white petrolatum avoid the patent?
It may avoid the narrower vehicle claims 19 and 26, but it does not automatically avoid claims 1-18. Those claims cover broader combinations involving the catechin mixture and isopropyl myristate.
Can the mathematical error in claim 26 invalidate the entire patent?
No. Any defect in claim 26 would generally be analyzed claim by claim. Claims 1-25 could remain enforceable if they independently satisfy the statutory requirements and are not otherwise invalidated.
References
- United States Patent and Trademark Office. (n.d.). Patent term calculator and patent term adjustment resources. https://www.uspto.gov/patents/laws/patent-term-calculator
- U.S. Food and Drug Administration. (n.d.). Veregen (sinecatechins) ointment prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
- United States Patent and Trademark Office. (2019). U.S. Patent No. 10,434,059. https://patents.google.com/patent/US10434059B2/en
